age1

Investment thesis

Early-stage firm (launched 2023) funding breakthrough companies targeting aging and age-related disease to extend healthy lifespan, shifting from treating individual diseases to preventing age-related onset. Prefers to lead the earliest rounds and doesn't require a pitch deck.

Sector focus